Dark

Check out our API

DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
stock NASDAQ

Inactive

Jun 10, 2024

25.59USD+0.078%(+0.02)1,591,389

Pre-market

0.00USD-100.000%(-25.57)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 24, 2022

05:00PM EST Deciphera Pharmaceuticals Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session Business Wire

Jan 23, 2022

11:03AM EST The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More Benzinga

Jan 10, 2022

07:00AM EST Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones Business Wire

Jan 3, 2022

07:00AM EST Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 21, 2021

08:56AM EST Deciphera Pharmaceuticals, Inc. (DCPH) announced the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for QINLOCK in the UK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. RTTNews

08:50AM EST Deciphera Announces Approval Of QINLOCK In UK For Treatment Of Fourth-Line Gastrointestinal Stromal Tumor RTTNews

08:45AM EST Deciphera Announces Approval Of QINLOCK In The United Kingdom For Treatment Of Fourth-Line Gastrointestinal Stromal Tumor Benzinga

08:44AM EST Deciphera Announces Approval of QINLOCK(r) in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Business Wire

Dec 1, 2021

06:15AM EST HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Lowers Price Target to $15 Benzinga

Nov 30, 2021

04:48PM EST Deciphera Pharmaceuticals Announces Restructuring Ro Prioritize Clinical Development Programs And Streamline Commercial Operations; Announces Workforce Reduction Of ~35% Benzinga

04:47PM EST Deciphera Pharmaceuticals Shares Halted On Code News Pending Benzinga

08:52AM EST Biopharmaceutical company Deciphera Pharmaceuticals, Inc. (DCPH) announced Tuesday a corporate restructuring intended to prioritize clinical development of select programs, streamline commercial operations, maintain a focus on discovery research and extend the Company's cash runway. RTTNews

08:39AM EST Deciphera Pharma To Reduce About 35% Or About 140 Positions RTTNews

08:30AM EST Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations Business Wire

Nov 22, 2021

07:23AM EST Deciphera Pharmaceuticals Inc. (DCPH) said that the European Commission has approved Qinlock or ripretinib in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. RTTNews

07:08AM EST Deciphera Receives European Commission Approval of QINLOCK for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Benzinga

07:07AM EST Deciphera Pharma Gets European Commission Approval Of QINLOCK For Fourth-Line Gastrointestinal Stromal Tumor RTTNews

07:00AM EST Deciphera Receives European Commission Approval of QINLOCK(r) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Business Wire

Nov 8, 2021

11:27AM EST What 6 Analyst Ratings Have To Say About Deciphera Pharmaceuticals Benzinga

09:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 Benzinga

08:53AM EST Truist Securities Downgrades Deciphera Pharmaceuticals to Hold, Lowers Price Target to $10 Benzinga

07:24AM EST 10 Biggest Price Target Changes For Monday Benzinga

06:48AM EST Canaccord Genuity Downgrades Deciphera Pharmaceuticals to Hold, Announces $12 Price Target Benzinga

06:28AM EST HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Lowers Price Target to $25 Benzinga

06:17AM EST Barclays Downgrades Deciphera Pharmaceuticals to Equal-Weight, Lowers Price Target to $11 Benzinga

05:27AM EST Stifel Downgrades Deciphera Pharmaceuticals to Hold Benzinga

Nov 5, 2021

02:57PM EDT Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher Benzinga

12:35PM EDT Mid-Day Market Update: Gold Rises 1%; Deciphera Pharmaceuticals Shares Plummet Benzinga

11:55AM EDT Truist Securities Downgrades Deciphera Pharmaceuticals to Hold, Lowers Price Target to $10 Benzinga

10:19AM EDT Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs Benzinga

09:45AM EDT JMP Securities Maintains Market Outperform on Deciphera Pharmaceuticals, Lowers Price Target to $64 Benzinga

09:39AM EDT Deciphera Shares Were Halted To Announce: INTRIGUE Phase 3 Study Did Not Meet Primary Endpoint Benzinga

07:59AM EDT Deciphera's INTRIGUE Phase 3 Clinical Study Fails To Yield RTTNews

07:29AM EDT Deciphera Pharma Says INTRIGUE Phase 3 Clinical Study Of QINLOCK Did Not Meet Primary Endpoint RTTNews

07:00AM EDT Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study Business Wire

Nov 2, 2021

04:20PM EDT Deciphera Pharmaceuticals Q3 EPS $(1.37) Misses $(1.28) Estimate, Sales $23.20M Miss $23.36M Estimate Benzinga

04:01PM EDT Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results Business Wire

10:54AM EDT The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga

10:41AM EDT Earnings Scheduled For November 2, 2021 Benzinga

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 26, 2021

07:00AM EDT Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 2, 2021 Business Wire

Oct 18, 2021

08:26AM EDT Deciphera Pharma Sponsored Study Titled 'Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor' Posted On ClinicalTrials.gov; Study Shows Not Yet Recruiting Benzinga

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

07:16AM EDT Deciphera Pharmaceuticals, Inc. (DCPH) announced the Swiss Agency for Therapeutic Products or Swissmedic, has granted approval for QINLOCK for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. RTTNews

07:15AM EDT Deciphera Announces Approval Of QINLOCK In Switzerland For The Treatment Of Fourth-Line Gastrointestinal Stromal Tumor Benzinga

07:09AM EDT Deciphera Pharma : Swissmedic Approves QINLOCK To Treat Fourth-Line Gastrointestinal Stromal Tumor RTTNews

07:00AM EDT Deciphera Announces Approval of QINLOCK(r) in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Business Wire

Oct 7, 2021

09:19AM EDT Deciphera Presents Preclinical Data From DCC-3116 Program At AACR-NCI-EORTC International Conference Benzinga

09:17AM EDT Deciphera Presents Preclinical Data From DCC-3116 Program On Molecular Targets And Cancer Therapeutics RTTNews

09:00AM EDT Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Business Wire

Sep 17, 2021

08:36AM EDT CHMP Adopts Positive Opinion For Deciphera's Qinlock To RTTNews

08:21AM EDT Deciphera Receives Positive CHMP Opinion For QINLOCK For Treatment Of Fourth-line Gastrointestinal Stromal Tumor RTTNews

08:18AM EDT Deciphera Announces Positive CHMP Opinion For QINLOCK For Treatment Of Fourth-Line Gastrointestinal Stromal Tumor Benzinga

08:17AM EDT Deciphera Announces Positive CHMP Opinion for QINLOCK(r) for the Treatment of Fourth-line Gastrointestinal Stromal Tumor Business Wire

07:10AM EDT Deciphera Pharma Highlights Presentation Of New Clinical Study Results Across Pipeline At European Society Of Medical Oncology Benzinga

07:00AM EDT Deciphera Pharmaceuticals Presents New Clinical Study Results Across Pipeline at the European Society for Medical Oncology (ESMO) Congress 2021 Business Wire

Sep 10, 2021

07:00AM EDT Deciphera Pharmaceuticals to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss Rebastinib and Vimseltinib Data Presented at ESMO Congress 2021 Business Wire

Sep 2, 2021

07:00AM EDT Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference Business Wire

Aug 20, 2021

01:50PM EDT Return on Capital Employed Insights for Deciphera Pharmaceuticals Benzinga

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

06:42AM EDT HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Lowers Price Target to $70 Benzinga

Aug 3, 2021

04:41PM EDT Deciphera Pharmaceuticals: Q2 Earnings Insights Benzinga

04:25PM EDT Deciphera Pharmaceuticals Q2 EPS $(1.21) Misses $(1.15) Estimate, Sales $23.57M Beat $22.00M Estimate Benzinga

04:02PM EDT Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results Business Wire

03:52AM EDT Earnings Scheduled For August 3, 2021 Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jun 30, 2021

04:02PM EDT Deciphera Pharma Reports First Patient Treated In Phase 1 Study Of DCC-3116 In Patients With Advanced, Metastatic Tumors With Mutant RAS, RAF Gene Benzinga

04:01PM EDT Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene Business Wire

Jun 4, 2021

09:15AM EDT Deciphera Pharmaceuticals Presents Data from QINLOCK and Rebastinib Programs at the 2021 American Society of Clinical Oncology Annual Meeting Benzinga

09:00AM EDT Deciphera Pharmaceuticals Presents Data from QINLOCK(r) and Rebastinib Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Business Wire

May 27, 2021

07:00AM EDT Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences Business Wire

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 11, 2021

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

06:24AM EDT HC Wainwright & Co. Maintains Buy on Deciphera Pharmaceuticals, Lowers Price Target to $75 Benzinga

May 4, 2021

05:11PM EDT Deciphera Pharmaceuticals Q1 EPS $(1.06) Beats $(1.07) Estimate, Sales $25.16M Beat $22.41M Estimate Benzinga

04:22PM EDT Deciphera Pharmaceuticals, Inc. Announces First Quarter 2021 Financial Results Business Wire

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

Apr 27, 2021

07:00AM EDT Deciphera Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 4, 2021 Business Wire

Mar 31, 2021

10:03AM EDT Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2021 Benzinga

07:04AM EDT Credit Suisse Initiates Coverage On Deciphera Pharmaceuticals with Outperform Rating, Announces Price Target of $78 Benzinga

04:58AM EDT China NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST GlobeNewswire Inc

Mar 2, 2021

07:00AM EST Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference Business Wire

Feb 18, 2021

07:01AM EST Deciphera Pharmaceuticals, Inc. to Present at the SVB Leerink 10th Annual Global Healthcare Conference Business Wire

Feb 10, 2021

10:05AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2021 Benzinga

08:42AM EST Barclays Maintains Overweight on Deciphera Pharmaceuticals, Lowers Price Target to $70 Benzinga

06:04AM EST SVB Leerink Upgrades Deciphera Pharmaceuticals to Outperform, Announces $70 Price Target Benzinga

Feb 9, 2021

05:31PM EST Recap: Deciphera Pharmaceuticals Q4 Earnings Benzinga

04:06PM EST Deciphera Pharmaceuticals Q4 EPS $(1.10) Beats $(1.15) Estimate, Sales $19.49M Beat $18.93M Estimate Benzinga

04:01PM EST Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2020 Financial Results Business Wire

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

04:05AM EST Earnings Scheduled For February 9, 2021 Benzinga

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Feb 4, 2021

07:00AM EST Deciphera Pharmaceuticals, Inc. to Present at the Guggenheim Healthcare Talks 2021 Idea Forum Oncology Day Business Wire

Feb 3, 2021

07:17AM EST Veracyte To Acquire Decipher Biosciences For Total Consideration Of $600 Mln RTTNews

Feb 2, 2021

07:00AM EST Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021 Business Wire

Jan 11, 2021

07:19AM EST Deciphera Pharma Provides 2021 Goals Benzinga

07:18AM EST Deciphera Pharma Provides Corporate Update And Highlights Key 2021 Corporate Milestones RTTNews

07:00AM EST Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones Business Wire

Jan 5, 2021

07:23AM EST Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 3, 2020

09:56AM EST Benzinga's Top Upgrades, Downgrades For December 3, 2020 Benzinga

Nov 30, 2020

07:07AM EST Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK in Patients with Second-Line Gastrointestinal Stromal Tumor Benzinga

07:00AM EST Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK(r) (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor Business Wire

Nov 24, 2020

04:01PM EST Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire

Nov 23, 2020

07:00AM EST The Boston Globe Names Deciphera a Top Place to Work for 2020 Business Wire

Nov 12, 2020

08:15AM EST 10 Biggest Price Target Changes For Thursday Benzinga

06:37AM EST SVB Leerink Maintains Market Perform on Deciphera Pharmaceuticals, Raises Price Target to $70 Benzinga

Nov 11, 2020

07:24AM EST Deciphera Presents Updated Preliminary Data From DCC-3014 At CTOS Meeting RTTNews

07:18AM EST Deciphera Presents Data From QINLOCK Program At CTOS 2020 Virtual Annual Meeting RTTNews

07:01AM EST Deciphera Presents Data from QINLOCK(r) (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting Business Wire

07:00AM EST Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual Meeting Business Wire

Nov 10, 2020

07:00AM EST Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference Business Wire

Nov 6, 2020

08:11AM EST Medison Pharma Enters Exclusive Distribution Agreement With Deciphera Pharmaceuticals To Commercialize QINLOCK (Ripretinib) In A Multi-Regional Agreement, No Terms Disclosed Benzinga

Nov 5, 2020

04:09PM EST Deciphera Pharmaceuticals Q3 EPS $(1.13) Beats $(1.30) Estimate, Sales $15.45M Beat $7.05M Estimate Benzinga

04:01PM EST Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial Results Business Wire

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 28, 2020

07:00AM EDT Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020 Business Wire

Sep 18, 2020

07:07AM EDT Deciphera Announces Presentation Of Nine Month Follow-up Data from Phase 3 INVICTUS Study Of QINLOCK RTTNews

07:04AM EDT Deciphera Pharma Reports Will Present 9-Month Follow-Up Data From Phase 3 INVICTUS Study Of QINLOCK In Patients With Fourth-Line Gastrointestinal Stromal Tumors At European Society For Medical Oncology Meeting Sept. 19-21 Benzinga

07:00AM EDT Deciphera Presents Data from QINLOCK(tm) (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Business Wire

Sep 17, 2020

07:05AM EDT Deciphera Presents Data from Rebastinib Its TIE2 Inhibitor Program At the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Benzinga

Sep 14, 2020

12:18PM EDT SVB Leerink Maintains Market Perform on Deciphera Pharmaceuticals, Raises Price Target to $58 Benzinga

Aug 17, 2020

04:34PM EDT Deciphera Announces The Publication Of QINLOCK Phase 1 Study Results In Patients With Gastrointestinal Stromal Tumor In Journal O Clinical Oncology Benzinga

04:30PM EDT Deciphera Announces Publication of QINLOCK(tm) (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical Oncology Business Wire

Aug 6, 2020

08:40AM EDT Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference Business Wire

Aug 5, 2020

06:30AM EDT SVB Leerink Maintains Market Perform on Deciphera Pharmaceuticals, Lowers Price Target to $54 Benzinga

Aug 4, 2020

05:18PM EDT Deciphera Pharmaceuticals Entered Into An Open Market Sale Agreement With Jefferies; May Issue And Sell Shares Of Common Stock Having Aggregate Offering Sales Proceeds Of Up To $200M From Time To Time Benzinga

04:22PM EDT Deciphera Pharmaceuticals Q2 EPS $(1.20) Beats $(1.37) Estimate, Sales $7.10M Beat $900.00K Estimate Benzinga

04:06PM EDT Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results Business Wire

05:19AM EDT Earnings Scheduled For August 4, 2020 Benzinga

Jul 29, 2020

07:00AM EDT Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020 Business Wire

Jul 20, 2020

07:40AM EDT Zai Lab And Deciphera Pharma: China NMPA Accepts NDA For Ripretinib For Advanced Gastrointestinal Stromal Tumor RTTNews

07:37AM EDT Zai Lab And Deciphera Announce China NMPA Accepts NDA Submission Of Ripretinib For Advanced Gastrointestinal Stromal Tumor Benzinga

07:30AM EDT China NMPA acceptance of NDA follows recent U.S. FDA approval for the treatment of adult patients with advanced GIST who have received prior treatment with 3 or more kinase inhibitors, including imatinib GlobeNewswire Inc

Jul 14, 2020

07:08AM EDT Deciphera Announces Australian Therapeutic Goods Administration Approval Of QINLOCK For Treatment Of Fourth-Line Gastrointestinal Stromal Tumor Benzinga

07:00AM EDT Deciphera Announces Australian Therapeutic Goods Administration's Approval of QINLOCK(tm) (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor Business Wire

Share